Overexpression of clusterin in human breast carcinoma

M. Redondo, E. Villar, J. Torres-Munoz, T. Tellez, M. Morell, Carol Petito

Research output: Contribution to journalArticle

212 Citations (Scopus)

Abstract

Clusterin has been implicated in numerous processes including active cell death, immune regulation, cell adhesion and morphological transformation. The purpose of this study was to examine clusterin expression in a large series of breast carcinomas by immunohistochemistry and in situ hybridization. The study included 40 samples of non-neoplastic glandular epithelia, 42 benign lesions, 15 atypical intraductal hyperplasias, 35 carcinomas in situ, 114 invasive carcinomas, and lymph node metastases from 40 patients. Epithelial normal cells were always negative for clusterin expression and only 19% of the benign lesions presented positive staining. In contrast to the benign lesions, however, the frequency of clusterin positive samples increased in atypical hyperplasias (47%, P = 0.08), intraductal carcinomas (49%, P = 0.01) and invasive carcinomas (53%, P < 0.001). Positive staining presented a cytoplasmic pattern, except in 3 cases of invasive carcinomas which had nuclear staining. Clusterin mRNA by in situ hybridization confirmed the specific cellular pattern of clusterin expression by immunohistochemistry. Clusterin expression was associated with large tumor size (P = 0.04), estrogen and progesterone receptor negative status (P = 0.02 and P = 0.001, respectively) and with the progression from primary carcinoma to metastatic carcinoma in lymph nodes (80% metastatic nodes had positive expression) (P = 0.004). Ten of 15 (67%) primary carcinomas without clusterin expression became positive in lymph node metastases, while most (22 of 25, 88%) of the clusterin-positive primary carcinomas were also immunoreactive in metastases. In survival analysis, clusterin expression did not represent a prognostic indicator by uni- or multivariate analysis. The increased clusterin expression in breast carcinomas tended to correlate inversely with the apoptotic index (P = 0.09) which indicates that clusterin gene expression is not a prerequisite to cellular death by apoptosis. From these results, we suggest that clusterin may have a role in tumorigenesis and progression of human breast carcinomas.

Original languageEnglish
Pages (from-to)393-399
Number of pages7
JournalAmerican Journal of Pathology
Volume157
Issue number2
StatePublished - Aug 29 2000

Fingerprint

Clusterin
Breast Neoplasms
Carcinoma
Lymph Nodes
Staining and Labeling
Neoplasm Metastasis
Hyperplasia
In Situ Hybridization
Immunohistochemistry
Carcinoma, Intraductal, Noninfiltrating
Carcinoma in Situ
Progesterone Receptors
Survival Analysis
Cell Adhesion
Estrogen Receptors

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Redondo, M., Villar, E., Torres-Munoz, J., Tellez, T., Morell, M., & Petito, C. (2000). Overexpression of clusterin in human breast carcinoma. American Journal of Pathology, 157(2), 393-399.

Overexpression of clusterin in human breast carcinoma. / Redondo, M.; Villar, E.; Torres-Munoz, J.; Tellez, T.; Morell, M.; Petito, Carol.

In: American Journal of Pathology, Vol. 157, No. 2, 29.08.2000, p. 393-399.

Research output: Contribution to journalArticle

Redondo, M, Villar, E, Torres-Munoz, J, Tellez, T, Morell, M & Petito, C 2000, 'Overexpression of clusterin in human breast carcinoma', American Journal of Pathology, vol. 157, no. 2, pp. 393-399.
Redondo M, Villar E, Torres-Munoz J, Tellez T, Morell M, Petito C. Overexpression of clusterin in human breast carcinoma. American Journal of Pathology. 2000 Aug 29;157(2):393-399.
Redondo, M. ; Villar, E. ; Torres-Munoz, J. ; Tellez, T. ; Morell, M. ; Petito, Carol. / Overexpression of clusterin in human breast carcinoma. In: American Journal of Pathology. 2000 ; Vol. 157, No. 2. pp. 393-399.
@article{1b37516f4aac4feab338a3592c5052d2,
title = "Overexpression of clusterin in human breast carcinoma",
abstract = "Clusterin has been implicated in numerous processes including active cell death, immune regulation, cell adhesion and morphological transformation. The purpose of this study was to examine clusterin expression in a large series of breast carcinomas by immunohistochemistry and in situ hybridization. The study included 40 samples of non-neoplastic glandular epithelia, 42 benign lesions, 15 atypical intraductal hyperplasias, 35 carcinomas in situ, 114 invasive carcinomas, and lymph node metastases from 40 patients. Epithelial normal cells were always negative for clusterin expression and only 19{\%} of the benign lesions presented positive staining. In contrast to the benign lesions, however, the frequency of clusterin positive samples increased in atypical hyperplasias (47{\%}, P = 0.08), intraductal carcinomas (49{\%}, P = 0.01) and invasive carcinomas (53{\%}, P < 0.001). Positive staining presented a cytoplasmic pattern, except in 3 cases of invasive carcinomas which had nuclear staining. Clusterin mRNA by in situ hybridization confirmed the specific cellular pattern of clusterin expression by immunohistochemistry. Clusterin expression was associated with large tumor size (P = 0.04), estrogen and progesterone receptor negative status (P = 0.02 and P = 0.001, respectively) and with the progression from primary carcinoma to metastatic carcinoma in lymph nodes (80{\%} metastatic nodes had positive expression) (P = 0.004). Ten of 15 (67{\%}) primary carcinomas without clusterin expression became positive in lymph node metastases, while most (22 of 25, 88{\%}) of the clusterin-positive primary carcinomas were also immunoreactive in metastases. In survival analysis, clusterin expression did not represent a prognostic indicator by uni- or multivariate analysis. The increased clusterin expression in breast carcinomas tended to correlate inversely with the apoptotic index (P = 0.09) which indicates that clusterin gene expression is not a prerequisite to cellular death by apoptosis. From these results, we suggest that clusterin may have a role in tumorigenesis and progression of human breast carcinomas.",
author = "M. Redondo and E. Villar and J. Torres-Munoz and T. Tellez and M. Morell and Carol Petito",
year = "2000",
month = "8",
day = "29",
language = "English",
volume = "157",
pages = "393--399",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Overexpression of clusterin in human breast carcinoma

AU - Redondo, M.

AU - Villar, E.

AU - Torres-Munoz, J.

AU - Tellez, T.

AU - Morell, M.

AU - Petito, Carol

PY - 2000/8/29

Y1 - 2000/8/29

N2 - Clusterin has been implicated in numerous processes including active cell death, immune regulation, cell adhesion and morphological transformation. The purpose of this study was to examine clusterin expression in a large series of breast carcinomas by immunohistochemistry and in situ hybridization. The study included 40 samples of non-neoplastic glandular epithelia, 42 benign lesions, 15 atypical intraductal hyperplasias, 35 carcinomas in situ, 114 invasive carcinomas, and lymph node metastases from 40 patients. Epithelial normal cells were always negative for clusterin expression and only 19% of the benign lesions presented positive staining. In contrast to the benign lesions, however, the frequency of clusterin positive samples increased in atypical hyperplasias (47%, P = 0.08), intraductal carcinomas (49%, P = 0.01) and invasive carcinomas (53%, P < 0.001). Positive staining presented a cytoplasmic pattern, except in 3 cases of invasive carcinomas which had nuclear staining. Clusterin mRNA by in situ hybridization confirmed the specific cellular pattern of clusterin expression by immunohistochemistry. Clusterin expression was associated with large tumor size (P = 0.04), estrogen and progesterone receptor negative status (P = 0.02 and P = 0.001, respectively) and with the progression from primary carcinoma to metastatic carcinoma in lymph nodes (80% metastatic nodes had positive expression) (P = 0.004). Ten of 15 (67%) primary carcinomas without clusterin expression became positive in lymph node metastases, while most (22 of 25, 88%) of the clusterin-positive primary carcinomas were also immunoreactive in metastases. In survival analysis, clusterin expression did not represent a prognostic indicator by uni- or multivariate analysis. The increased clusterin expression in breast carcinomas tended to correlate inversely with the apoptotic index (P = 0.09) which indicates that clusterin gene expression is not a prerequisite to cellular death by apoptosis. From these results, we suggest that clusterin may have a role in tumorigenesis and progression of human breast carcinomas.

AB - Clusterin has been implicated in numerous processes including active cell death, immune regulation, cell adhesion and morphological transformation. The purpose of this study was to examine clusterin expression in a large series of breast carcinomas by immunohistochemistry and in situ hybridization. The study included 40 samples of non-neoplastic glandular epithelia, 42 benign lesions, 15 atypical intraductal hyperplasias, 35 carcinomas in situ, 114 invasive carcinomas, and lymph node metastases from 40 patients. Epithelial normal cells were always negative for clusterin expression and only 19% of the benign lesions presented positive staining. In contrast to the benign lesions, however, the frequency of clusterin positive samples increased in atypical hyperplasias (47%, P = 0.08), intraductal carcinomas (49%, P = 0.01) and invasive carcinomas (53%, P < 0.001). Positive staining presented a cytoplasmic pattern, except in 3 cases of invasive carcinomas which had nuclear staining. Clusterin mRNA by in situ hybridization confirmed the specific cellular pattern of clusterin expression by immunohistochemistry. Clusterin expression was associated with large tumor size (P = 0.04), estrogen and progesterone receptor negative status (P = 0.02 and P = 0.001, respectively) and with the progression from primary carcinoma to metastatic carcinoma in lymph nodes (80% metastatic nodes had positive expression) (P = 0.004). Ten of 15 (67%) primary carcinomas without clusterin expression became positive in lymph node metastases, while most (22 of 25, 88%) of the clusterin-positive primary carcinomas were also immunoreactive in metastases. In survival analysis, clusterin expression did not represent a prognostic indicator by uni- or multivariate analysis. The increased clusterin expression in breast carcinomas tended to correlate inversely with the apoptotic index (P = 0.09) which indicates that clusterin gene expression is not a prerequisite to cellular death by apoptosis. From these results, we suggest that clusterin may have a role in tumorigenesis and progression of human breast carcinomas.

UR - http://www.scopus.com/inward/record.url?scp=0033903190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033903190&partnerID=8YFLogxK

M3 - Article

C2 - 10934144

AN - SCOPUS:0033903190

VL - 157

SP - 393

EP - 399

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 2

ER -